Intellectual Property - May 11, 2022
BioArctic receives new drug substance patent in the US
BioArctic has announced that the US Patent and Trademark Office (USPTO) has granted a new drug substance patent for the antibody ABBV-0805, invented by BioArctic as a potential treatment of Parkinson’s disease. The patent will take effect on May 24, 2022, and expire in 2041, with the possibility of a patent term extension up until […]
Agreement - April 20, 2022
AbbVie terminates collaboration with BioArctic
BioArctic has announced that the company’s partner AbbVie has decided to terminate its collaboration with BioArctic regarding the portfolio of alpha-synuclein antibodies, including ABBV-0805. BioArctic and AbbVie have collaborated since 2016 regarding the research and development of BioArctic’s portfolio of alpha-synuclein antibodies for Parkinson’s disease and other potential indications. In 2019, a Phase 1 study […]
Biotech Business - June 30, 2021
BioArctic’s lecanemab granted Breakthrough Therapy designation
BioArctic’s partner Eisai has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for lecanemab (BAN2401). BAN2401 is an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer’s disease. Based on a Phase 2b trial The FDA’s Breakthrough Therapy designation for lecanemab is based on the recently published […]
Agreement - May 5, 2021
Alligator Bioscience and BioArctic collaborate
The two companies have entered into a joint research agreement. Under the agreement, Alligator will employ its antibody generation technologies in collaboration with BioArctic to develop new product candidates, it states in a press release. “We are very pleased that BioArctic has recognized the power of Alligator’s proprietary phage display libraries which have been successfully […]
Clinical Trials - April 6, 2021
New data from BioArctic and Eisai
The companies have announced data on the drug candidate lecanemab (BAN2401). The presentations included findings suggesting that lecanemab could be of potential benefit for adults with Down’s syndrome with signs of functional or cognitive deterioration. Preliminary results presented from the ongoing open-label extension of the Phase 2b study in early Alzheimer’s disease continue to support […]
Intellectual Property - February 1, 2021
BioArctic receives European patent
BioArctic has announced that the European Patent Office (EPO) has issued a decision to grant the European patent for novel antibodies that could be developed into a treatment for Alzheimer’s disease. The antibodies target a shorter (truncated) form of amyloid beta (pE3-Aβ) and are linked to the company’s project AD1503. The patent enters into force […]
